<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522872</url>
  </required_header>
  <id_info>
    <org_study_id>TH-CR-408</org_study_id>
    <nct_id>NCT01522872</nct_id>
  </id_info>
  <brief_title>Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and&#xD;
      dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory&#xD;
      multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the initial study of TH-302 in subjects with relapsed/refractory multiple myeloma. It&#xD;
      is an open-label dose-escalation study to determine the DLTs, MTD, safety and preliminary&#xD;
      efficacy of TH-302 and dexamethasone with a Simon two-stage expansion at the MTD. The study&#xD;
      will also investigate the DLTs, MTD, safety and preliminary efficacy of TH-302, dexamethasone&#xD;
      and bortezomib; and the DLTs, MTD, safety and preliminary efficacy of TH-302, dexamethasone&#xD;
      and pomalidomide. As such, the study is separated into four parts. Treatment will be&#xD;
      administered until disease progression or unacceptable toxicity, or 12 cycles (Arm A, Arm B&#xD;
      and Arm C) or 9 cycles (Arm D) have been completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of adverse events(AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events(AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of TH-302 and dexamethasone with or without bortezomib or pomalidomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>recommended Phase 2 dose for TH-302 and dexamethasone with or without bortezomib or pomalidomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between hypoxia within the bone marrow of subjects with relapsed/refractory multiple myeloma and response to TH-302 and dexamethasone with or without bortezomib or pomalidomide using markers of hypoxia</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of TH-302 and bortezomib</measure>
    <time_frame>Cycle 1 Day 1 predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Monotherapy TH-302 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 and Dexamethasone Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Pomalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302</intervention_name>
    <arm_group_label>Monotherapy TH-302 Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 and Dexamethasone</intervention_name>
    <arm_group_label>TH-302 and Dexamethasone Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib</intervention_name>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Bortezomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide</intervention_name>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Pomalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age.&#xD;
&#xD;
          2. Ability to understand the purposes and risks of the study and has signed a written&#xD;
             informed consent form approved by the investigator's IRB/Ethics Committee.&#xD;
&#xD;
          3. Relapsed/refractory multiple myeloma for which no standard therapy options are&#xD;
             anticipated to result in a durable remission.&#xD;
&#xD;
          4. Receipt of at least two prior therapies as indicated by protocol&#xD;
&#xD;
          5. Subjects with measurable disease&#xD;
&#xD;
          6. ECOG performance status of less than or equal to 2&#xD;
&#xD;
          7. Acceptable liver function&#xD;
&#xD;
          8. Acceptable renal function&#xD;
&#xD;
          9. Acceptable hematologic status&#xD;
&#xD;
         10. For Part A, B, C subjects: Women of childbearing potential must have a negative serum&#xD;
             pregnancy test and women and men subjects must agree to use effective means of&#xD;
             contraception with their partner as indicated by protocol For Part D subjects: a&#xD;
             negative serum pregnancy test is required within 10- 14 days prior to initiating with&#xD;
             pomalidomide, AND a negative serum pregnancy test within 24 hours of starting&#xD;
             pomalidomide and must either commit to continued abstinence from heterosexual&#xD;
             intercourse or begin two acceptable methods of birth control at least 28 days before&#xD;
             she starts taking pomalidomide.&#xD;
&#xD;
             Women of childbearing potential must enroll into and follow all requirements of the&#xD;
             POMALYST REMS program, which includes adhering to the scheduled pregnancy testing.&#xD;
&#xD;
             Men must agree to use a latex or synthetic condom during sexual contact with women of&#xD;
             child bearing potential even if they have had a vasectomy.&#xD;
&#xD;
             All subjects must be counseled at a minimum of every 28 days about pregnancy&#xD;
             precautions and risks of fetal exposure, or when a female patient misses her period or&#xD;
             if there is any abnormality in her menstrual bleeding.&#xD;
&#xD;
         11. Subjects must adhere to the study visit schedule and other protocol requirements and&#xD;
             receive outpatient therapy and laboratory monitoring at the institute that administers&#xD;
             the study drug.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria are not eligible to be enrolled&#xD;
        in this study:&#xD;
&#xD;
          1. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy&#xD;
             and skin changes.)&#xD;
&#xD;
          2. Waldenstrom's macroglobulinemia&#xD;
&#xD;
          3. Localized radiation therapy to only measurable disease site(s) within 2 weeks of&#xD;
             treatment&#xD;
&#xD;
          4. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial&#xD;
             infarction within 6 months prior to Day 1, or unstable arrhythmia&#xD;
&#xD;
          5. Significant neuropathy (Grade 3 or 4, or Grade 2 with pain) at the time of enrollment&#xD;
             or within 14 days before enrollment&#xD;
&#xD;
          6. Symptomatic brain metastases (unless previously treated and well controlled for a&#xD;
             period of â‰¥ 3 months)&#xD;
&#xD;
          7. Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the&#xD;
             investigator any physiological state leading to hypoxemia&#xD;
&#xD;
          8. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without&#xD;
             complete recovery&#xD;
&#xD;
          9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy within 14 days prior to the first dose&#xD;
&#xD;
         10. Previously treated malignancies, except for adequately treated non-melanoma skin&#xD;
             cancer (basal cell or squamous cell), in situ cancer, or other cancer from which the&#xD;
             subject has been disease-free for at least 5 years&#xD;
&#xD;
         11. Subjects who participated in an investigational drug or device study within 2 weeks&#xD;
             prior to study entry&#xD;
&#xD;
         12. Known or suspected active infection with HIV, hepatitis A, hepatitis B, or hepatitis C&#xD;
&#xD;
         13. Subjects who have exhibited allergic reactions to a similar structural compound,&#xD;
             biological agent, or formulation similar to TH-302, bortezomib (for subjects enrolled&#xD;
             in Part C only), pomalidomide (Part D), dexamethasone or pimonidazole&#xD;
&#xD;
         14. Females who are pregnant or breast-feeding&#xD;
&#xD;
         15. Concomitant psychiatric disease or medical condition that could interfere with the&#xD;
             conduct of the study, or that would, in the opinion of the investigator, pose an&#xD;
             unacceptable risk to the subject in this study&#xD;
&#xD;
         16. Unwillingness or inability to comply with the study protocol for any reason&#xD;
&#xD;
         17. Previous cytotoxic therapies for multiple myeloma within 3 weeks prior to study entry&#xD;
             (2 weeks for biologic, novel therapy or corticosteroids)&#xD;
&#xD;
         18. Subjects who have been on hormone replacement less than 2 months (subjects on hormone&#xD;
             replacement for at least 2 months will not be excluded provided the HRT regimen&#xD;
             remains unchanged during the conduct of the study).&#xD;
&#xD;
         19. Prior peripheral stem cell transplant within 12 weeks of the start of study&#xD;
&#xD;
         20. Epilepsy or other convulsive disorder requiring active management&#xD;
&#xD;
         21. Prior therapy with a pomalidomide-containing regimen&#xD;
&#xD;
         22. Subjects on strong inducers or strong inhibitors of cytochrome P450 CYP3A4 or CYP1A2&#xD;
&#xD;
         23. Any other medical condition that in opinion of investigator would place patient at&#xD;
             increased risk for toxicity during pomalidomide treatment (i.e. history of recurrent&#xD;
             or serious thromboembolic events)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Southaven</city>
        <state>Mississippi</state>
        <zip>38671</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Hudson</city>
        <state>New York</state>
        <zip>12534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TH-302</keyword>
  <keyword>Relapsed/Refractory Multiple Myeloma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Phase 1/2</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Evofosfamide</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Pimonidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Phosphoramide Mustards</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

